Axogen director sells 11,050 shares after option exercise

Axogen, Inc. director John Johnson exercised stock options and sold the resulting shares.

Rhea-AI Filing Summary

Axogen, Inc. director John Johnson exercised stock options and sold the resulting shares. On May 7, 2026, he exercised options covering 11,050 shares of common stock at $7.04 per share, then sold 11,050 shares in open-market transactions at a weighted average price of $43.255 per share. The sale price reflected multiple trades between $43.25 and $43.35 per share. Following these transactions, Johnson reported holding 0 shares of Axogen common stock directly, and the exercised option grant was fully used.

Insider Trade Summary

Exercise and Sale: 11,050 shares ($400K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider JOHNSON JOHN

Role Director

Sold 11,050 shs ($478K)

Approx. gross sale proceeds $478K

Approx. exercise cost $78K

Approx. pre-tax spread $400K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to purchase)	11,050	$0.00	$0.00
Exercise	Common Stock	11,050	$7.04	$78K
Sale	Common Stock	11,050	$43.255	$478K

Holdings After Transaction: Employee Stock Option (right to purchase) — 0 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.25 to $43.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. All shares of Axogen, Inc. common stock underlying the board of director stock option were fully vested on June 6, 2025.

Key Figures

Shares sold: 11,050 shares Weighted average sale price: $43.255 per share Sale price range: $43.25–$43.35 per share +3 more

6 metrics

Shares sold 11,050 shares Common stock sold in open market on May 7, 2026

Weighted average sale price $43.255 per share Open-market sales on May 7, 2026

Sale price range $43.25–$43.35 per share Multiple transactions on May 7, 2026

Options exercised 11,050 shares Employee stock option exercise on May 7, 2026

Option exercise price $7.04 per share Employee stock option (right to purchase) for common stock

Shares held after 0 shares Direct common stock ownership following transactions

Key Terms

weighted average sale price, Employee Stock Option (right to purchase), derivative exercise/conversion, board of director stock option

4 terms

weighted average sale price financial

"The reported price in Column 4 is a weighted average sale price."

Employee Stock Option (right to purchase) financial

"security_title": "Employee Stock Option (right to purchase)""

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

board of director stock option financial

"All shares of Axogen, Inc. common stock underlying the board of director stock option were fully vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Axogen (AXGN) director John Johnson report?

John Johnson reported exercising options for 11,050 Axogen shares at $7.04 and selling 11,050 common shares in open-market trades at a weighted average price of $43.255 per share, all on May 7, 2026.

How many Axogen (AXGN) shares did John Johnson sell and at what price?

John Johnson sold 11,050 Axogen common shares in open-market transactions at a weighted average price of $43.255 per share. The trades occurred in a price range between $43.25 and $43.35 per share on May 7, 2026.

What stock options did Axogen (AXGN) director John Johnson exercise?

John Johnson exercised an employee stock option to purchase 11,050 Axogen common shares at an exercise price of $7.04 per share. All shares underlying this board of director stock option were fully vested as of June 6, 2025, before the exercise.

What are John Johnson’s Axogen (AXGN) holdings after these transactions?

After exercising options and selling the resulting 11,050 Axogen common shares, John Johnson reported owning 0 shares of Axogen common stock directly. The derivative position related to the exercised employee stock option was also reduced to zero in this filing.

How does the Form 4 describe the Axogen (AXGN) sale pricing details?

The Form 4 states that the reported sale price of $43.255 is a weighted average. Shares were sold in multiple transactions at prices ranging from $43.25 to $43.35 per share, and detailed trade information is available upon request from the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON JOHN

(Last) (First) (Middle)

C/O AXOGEN, INC. 13631 PROGRESS BLVD.

SUITE 400

(Street)

ALACHUA FLORIDA 32615

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026	05/07/2026	M		11,050	A	$7.04	11,050	D
Common Stock	05/07/2026	05/07/2026	S		11,050	D	$43.255(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to purchase)	$7.04	05/07/2026	05/07/2026	M			11,050	(2)	06/06/2034	Common Stock	11,050	$0	0	D

Explanation of Responses:

1. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.25 to $43.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. All shares of Axogen, Inc. common stock underlying the board of director stock option were fully vested on June 6, 2025.

Remarks:

	/S/ Marc Began, as attorney-in-fact for John Johnson	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)